2 results
Approved WMOCompleted
To evaluate the efficacy of NEOD001 plus standard of care vs. placebo plus standard of care when administered intravenously in subjects with AL amyloidosis by assessing time to all-cause mortality or cardiac hospitalizationSecondary ObjectivesIn…
Approved WMOPending
This is a clinical performance study of PD-L1 IHC 22C3 pharmDx on non-squamous non-small cell lung cancer specimens. PD-L1 IHC 22C3 pharmDx will be used to select non-squamous NSCLC patients eligible for the TROPION-Lung07…